Chia-Hung Chen's Biography

Chia-Hung Chen, Associate Professor, City University of Hong Kong

Dr. Chen Chia-Hung is an Associate Professor in the Department of Biomedical Engineering at City University of Hong Kong. He obtained his Ph.D. at the University of Cambridge, followed by postdoctoral studies at the Massachusetts Institute of Technology. Dr. Chen is exploiting high-throughput microfluidic devices, and artificial intelligent technologies for comprehensive analysis of cellular heterogeneity in human health and disease. He aims to innovate advanced tools to revolutionize diagnosis, and therapeutical strategies of complex human diseases including cancers to enable precision medicine. Notably, Dr. Chen has authored over 75 peer-reviewed journal papers. He was awarded more than 25 international competitive external funds as a principal investigator and was an editorial board member in Biomicrofluidics. Moreover, he collaborated with the clinicians and industrial partners from diverse backgrounds to develop the commercial devices for translational medicine.

Intelligent Droplet Screen for High-Throughput Single Cell Level Tumor Profiling on Extracellular Matrix

Wednesday, 26 July 2023 at 15:00

Add to Calendar ▼2023-07-26 15:00:002023-07-26 16:00:00Europe/LondonIntelligent Droplet Screen for High-Throughput Single Cell Level Tumor Profiling on Extracellular MatrixMicrophysiological Systems 2023: A Deep Dive into Technologies and Applications in Orlando, FloridaOrlando, FloridaSELECTBIOenquiries@selectbiosciences.com

Precision cancer treatment refers to providing a personalized therapeutic strategy in time to maximize treatment efficiency and minimize the side effect of drugs. Individual cancer cells interact with the extracellular matrix (ECM), showing distinct endogenous drug resistance and therapeutic responses. The responses of cancer cells to mechanical cues from the ECM especially influence cancer progression and metastasis. It is therefore becoming clear that comprehensive approaches are needed to address single-cell functional profiling of patient tumor samples. The overall goals of this study are as follows: 1. develop an intelligent high-throughput single-cell screening platform integrated with smart hydrogel technology that allows the isolation of treatment-resistant cancer cells on ECM in patient tumors with an ultrahigh throughput of ~100 cells/second; and 2. identify and validate candidate therapeutic targets and biomarkers for rare critical cells representing drug treatment-resistant and/or metastatic subclones for therapeutic stratification. The hypothesis-driven therapeutics could be tested to provide a rationale for the inclusion of novel therapeutic targets and repositioning of existing drugs in cancer treatment regimens.

Add to Calendar ▼2023-07-26 00:00:002023-07-27 00:00:00Europe/LondonMicrophysiological Systems 2023: A Deep Dive into Technologies and ApplicationsMicrophysiological Systems 2023: A Deep Dive into Technologies and Applications in Orlando, FloridaOrlando, FloridaSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors

	Organoids and Spheroids Europe 2024 Location: Rotterdam, The Netherlands Date: 24/06/2024 - 25/06/2024

	Lab-on-a-Chip and Microfluidics Europe 2024 Location: Rotterdam, The Netherlands Date: 24/06/2024 - 25/06/2024

	Innovations in Microfluidics 2024: Rapid Prototyping, 3D-Printing Location: Ann Arbor, Michigan Date: 06/05/2024 - 07/05/2024